{"brief_title": "Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma", "brief_summary": "To determine what side effects and what clinical effect, if any, the administration of this investigational product, IDEC-114 in combination with Rituxan\u00ae [Rituxan\u00ae as a single agent is approved by the United States Food and Drug Administration (FDA) to treat patients with relapsed or refractory follicular NHL], has in this patient population.", "condition": "Non-Hodgkin's Lymphoma", "intervention_type": "Drug", "intervention_name": "IDEC-114", "description": "Dose Group 1 - 125 mg/m2 x 4 infusions & 375 mg/m2 Rituxan x 4 infusions Dose Group 2 - 250 mg/m2 x 4 infusions & 375 mg/m2 Rituxan x 4 infusions Dose Group 3 - 375 mg/m2 x 4 infusions & 375 mg/m2 Rituxan x 4 infusions Dose Group 4 - 500 mg/m2 x 4 infusions & 375 mg/m2 Rituxan x 4 infusions", "arm_group_label": "1", "criteria": "Inclusion Criteria: - Signed IRB-approved informed consent - Greater than or equal to 18 years of age - Proof of follicular lymphoma - Progressive disease requiring treatment after at least 1 prior standard therapy - Acceptable hematologic status, liver function, and renal function - Patients of reproductive potential must agree to follow accepted birth control methods during treatment and for 3 months after completion of treatment Exclusion Criteria: - No response to prior Rituxan\u00ae or Rituxan\u00ae-containing regimen - Presence of CLL or CNS lymphoma - Known history of HIV infection or AIDS - Prior diagnosis of aggressive NHL or mantle-cell lymphoma - Serious nonmalignant disease - Pregnant or currently breast feeding", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00048555.xml"}